XNK Therapeutics AB (“XNK”) today announced it strengthened its organization by appointing Agneta Edberg to the board of directors.
Agneta Edberg has over 25 years’ experience from leading positions in the life sciences industry. She has been CEO at Mylan Nordic AB and the Swedish Pharmaceutical Insurance and has held leading positions within Pfizer, Bactiguard and Cilag (Johnson & Johnson).
Edberg has extensive experience from several board assignments among other as chairman of the board of Immunicum AB, an immuno-oncology company listed on Nasdaq Stockholm and chairman of the board of Idogen AB, a company engineering immune-tolerance based on dendritic cells. She also participates on the board of the Vinnova project CAMP, Centre for Advanced Medical Products, a public private partnership consortium to accelerate new breakthrough ATMP therapies to patients.
For more information, please contact:
Karin Mellström, CEO, XNK Therapeutics
E-mail: info@xnktherapeutics.com
About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit xnktherapeutics.com.
About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen.
